Analytical characterization of ch14.18: A mouse-human chimeric disialoganglioside-specific therapeutic antibody

mAbs

Volumn 4, Issue 1, 2012, Pages 84-100

  Soman, Gopalan ^a   Kallarakal, Abraham T ^a   Michiel, Dennis ^a   Yang, Xiaoyi ^a   Saptharishi, Nirmala ^a   Jiang, Hengguang ^a   Giardina, Steve ^a   Gilly, John ^a   Mitra, George ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Characterization assays; Chimeric antibody; Complement dependent cytotoxicity; Fc RIIIA:ch14.18 interaction; Imaged cIEF; Monoclonal antibodies; N glycan analysis; N glycoprofiling; SEC MALS; Surface plasmon resonance

Indexed keywords

ANTHRANILIC ACID; CD16 ANTIGEN; CHIMERIC ANTIBODY; CHIMERIC ANTIBODY CH14 18; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; GLYCAN; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BIOSENSOR; CAPILLARY ELECTROPHORESIS; CELL PROLIFERATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ION EXCLUSION CHROMATOGRAPHY; LIGHT SCATTERING; PROTEIN INTERACTION; REPRODUCIBILITY; SCALE UP; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG STABILITY; GANGLIOSIDES; HUMANS; MICE; NEUROBLASTOMA; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 84863014565     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.4.1.18566     Document Type: Article

References (42)

1. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073-8; PMID:16151394; http://dx.doi.org/10.1038/nbt0905-1073.
2. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6:349-56; PMID:17431406; http://dx.doi.org/10.1038/nrd2241.
3. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000; 21:403-10; PMID:10916144; http://dx.doi.org/10.1016/S0167-5699(00) 01669-8.
4. Shapiro MA, Swann PG, Hartsough M. Regulatory considerations in the development of monoclonal antibodies for diagnosis and therapy. In: Dubel S, Editor. Handbook of Therapeutic Antibodies. Weinham, Germany: Wiley VCH 2005.
5. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22:1383-91; PMID:15529163; http://dx.doi.org/10.1038/nbt1030.
6. Kozlowski S, Swann PG. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv Drug Deliv Rev 2006; 58:707-22; PMID:16828921; http://dx.doi.org/10.1016/j.addr.2006.05.002.
7. Woodcock J, Griffin J, Behrman R, Cherney B, Crescenzi T, Fraser B, et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov 2007; 6:437-42; PMID:17633790; http://dx.doi.org/10.1038/nrd2307.
8. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability and formulation. J Pharm Sci 2007; 96:1-26; PMID:16998873; http://dx.doi.org/ 10.1002/jps.20727.
9. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure- immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21:897-903; PMID:15212151; http://dx.doi.org/10.1023/B:PHAM.0000029275.41323.a6.
10. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8:501-7; PMID:17025268; http://dx.doi.org/10.1208/aapsj080359.
11. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991; 51:144-9; PMID:1988079.
12. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004; 22:3549-57; PMID:15337804; http://dx.doi.org/10.1200/JCO.2004.08.143.
13. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, et al. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin Padiatr 2005; 217:147-52; PMID:15858706; http://dx.doi.org/10.1055/s-2005-836518.
14. Hartmann WK, Saptharishi N, Yang XY, Mitra G, Soman G. Characterization and analysis of thermal denaturation of antibodies by size exclusion high-performance liquid chromatography with quadruple detection. Anal Biochem 2004; 325:227-39; PMID:14751257; http://dx.doi.org/10.1016/j.ab.2003.10.031.
15. Anumula KR, Dhume ST. High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid. Glycobiology 1998; 8:685-94; PMID:9621109; http://dx.doi.org/10.1093/glycob/8.7.685.
16. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 2009; 30:356-62; PMID:19552968; http://dx.doi.org/10.1016/j.tips.2009.04.007.
17. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 1989; 49:2857-61; PMID:2720646.
18. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990; 144:1382-6; PMID:2303711.
19. Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 1986; 83:7893-7; PMID:3094017; http://dx.doi.org/10.1073/pnas.83.20. 7893.
20. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991; 51:144-9; PMID:1988079.
21. Robinson CJ, Jones C. Quality control and analytical techniques for biopharmaceuticals. Bioanalysis 2011; 3:81-95; PMID:21175369; http://dx.doi.org/10.4155/bio.10.161.
22. Vázquez-Rey M, Lang DA. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng 2011; 108:1494-508; PMID:21480193; http://dx.doi.org/10.1002/bit.23155.
23. Soman G, Yang XY, Jiang H, Giardina S, Mitra G. Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA. J Immunol Methods 2011; 373:181-91; PMID:21893062; http://dx.doi.org/10.1016/j.jim.2011.08.016.
24. Janini G, Saptharishi N, Waselus M, Soman G. Element of a validation method for MU-B3 monoclonal antibody using an imaging capillary isoelectric focusing system. Electrophoresis 2002; 23:1605-11; PMID:12179978; http://dx.doi.org/10.1002/1522-2683(200206)23:11〈1605::AID-ELPS1605〉3. 0.CO;2-O.
25. Soman G, Saptharishi N, Janini GM, Mitra G. Imaged capillary isoelectric focusing of proteins. Bioforum Int 2002; 6:263-7.
26. Sharma VK, Kalonia DS. Experimental detection and characterization of protein aggregates. In: Wang W, Robert CJ, Eds. Aggregation of Therapeutic Proteins: John Wiley and Sons Publishing, NJ USA 2010; 205-56.
27. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 2010; 99:3302-21; PMID:20310025; http://dx.doi.org/10.1002/jps.22097.
28. Narhi LO, Jiang Y, Cao S, Benedek K, Shnek D. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 2009; 10:373-81; PMID:19519412; http://dx.doi.org/10.2174/138920109788488905.
29. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011; 21:949-59; PMID:21421994; http://dx.doi.org/10.1093/glycob/cwr027.
30. Chen X, Liu YD, Flynn GC. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 2009; 19:240-9; PMID:18974198; http://dx.doi.org/10.1093/glycob/cwn120.
31. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200.
32. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200.
33. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIII. Biotechnol Bioeng 2001; 74:288-94; PMID:11410853; http://dx.doi.org/10.1002/bit.1119.
34. Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21:1644-52; PMID:16321047; http://dx.doi.org/10.1021/bp050228w.
35. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761.
36. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10:101-11; PMID:21283105; http://dx.doi.org/10.1038/nrd3365.
37. Griggs J, Zinkewich-Peotti K. The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. Br J Cancer 2009; 101:1807-12; PMID:19809433; http://dx.doi.org/10.1038/sj.bjc.6605349.
38. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10. 1038/nri2206.
39. Zeck A, Pohlentz G, Schlothauer T, Peter-Katalinić J, Regula JT. Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa. J Proteome Res 2011; 10:3031-9; PMID:21561106; http://dx.doi.org/10.1021/ pr1012653.
40. Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee M. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin Cancer Res 1997; 3:1969-76; PMID:9815586.
41. Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K. Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res 2001; 61:4244-52; PMID:11358851.
42. Yang X, Chen E, Jiang H, Muszynski K, Harris RD, Giardina SL, et al. Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. J Virol Methods 2009; 155:44-54; PMID:18951922; http://dx.doi.org/10.1016/j.jviromet.2008.09.020.